| You are here: Home: BCU 9|2003 - Supplement : Case 7: From the practice of Gregory R Favis, MD: Select publications
Select publications
Single agent versus combination chemotherapy in the metastatic setting
Ahn Sr, JH et al. Phase II study of combination chemotherapy of capecitabine and vinorelbine in metastatic breast cancer with previous exposure to anthracycline and taxane: Preliminary results. Proc ASCO 2002; Abstract 2030.
Alba E et al. Multicenter Phase III randomized trial comparing sequential versus concomitant administration of doxorubicin (A) and docetaxel (T) as first-line treatment of metastatic breast cancer (MBC). GEICAM 9903 Study. Proc ASCO 2003;Abstract 27.
Ghosn M et al. Vinorelbine (Navelbine) IV and capecitabine (vinocap) as front-line chemotherapy in metastatic breast cancer (MBC). Proc ASCO 2002;Abstract 1978.
Miles D et al. Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 2002;7(Suppl 6):13-9. Erratum in: Oncologist 2003;8(1):127. Abstract
Miles D et al. Survival benefit with Xeloda (capecitabine)/docetaxel vs docetaxel: Analysis of post-study therapy. Breast Cancer Res Treat 2001;Abstract 442.
O'Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract
Seidman AD et al. Single-agent capecitabine: A reference treatment for taxane-pretreated metastatic breast cancer? Oncologist 2002;7 (Suppl 6)20-8. Abstract
Sledge GW et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). J Clin Oncol 2003;21(4):588-92. Abstract
Tripathy D. Overview: Gemcitabine as single-agent therapy for advanced breast cancer. Clin Breast Cancer 2002;3 (Suppl 1)8-11. Abstract
Twelves C et al. Adding Xeloda (capecitabine) to docetaxel significantly improves survival and does not compromise quality of life in patients with metastatic breast cancer. Breast Cancer Res Treat 2001;Abstract 542.
Wright TL, Twelves CJ. Improved survival in advanced breast cancer with docetaxel and capecitabine in combination: Biological synergy or an artifact of trial design? Eur J Cancer 2002;38:1957-60. Abstract
|
